Hematological and molecular response evaluation of CML patients on imatinib

A. Gupta, K. Prasad

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background : The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. Aims : To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. Methods and Materials : Sixteen patients were diagnosed as having chronic phase CML at Kasturba Medical College Hospital, Attavar, Mangalore during the period of two years from January 2004 to January 2006 and were given Imatinib at 400 mg/day orally. They were followed closely over a period of 1 year using the following parameters: (1) monthly clinical examination, (2) monthly peripheral blood smear examination, (3) real time reverse transcriptase quantitative polymerase chain reaction (RT Q-PCR) for BCR-ABL at the end of every 6 months. The findings were evaluated after one year for hematological and molecular response achieved. Results: Fifteen (93.75%) patients achieved complete hematological response within three months of therapy. Six (37.5%) patients achieved complete molecular response(CMR) within six months of therapy as measured by real time RT Q-PCR. None of the patients who did not achieve CMR within first six months of therapy achieved it after one year of therapy. No patient lost the initial response. The median BCR - ABL/ABL value at the end of the six months was 11% and at the end of the one year was 3.38%. Conclusion: Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be used as a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalJournal of Association of Physicians of India
Volume55
Issue numberFEB.
Publication statusPublished - 01-02-2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Therapeutics
Reverse Transcriptase Polymerase Chain Reaction
Cytogenetics
Protein-Tyrosine Kinases
Real-Time Polymerase Chain Reaction
Imatinib Mesylate
Bone Marrow
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{cc3e7d0afaa84d088063a221bef5cc8e,
title = "Hematological and molecular response evaluation of CML patients on imatinib",
abstract = "Background : The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. Aims : To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. Methods and Materials : Sixteen patients were diagnosed as having chronic phase CML at Kasturba Medical College Hospital, Attavar, Mangalore during the period of two years from January 2004 to January 2006 and were given Imatinib at 400 mg/day orally. They were followed closely over a period of 1 year using the following parameters: (1) monthly clinical examination, (2) monthly peripheral blood smear examination, (3) real time reverse transcriptase quantitative polymerase chain reaction (RT Q-PCR) for BCR-ABL at the end of every 6 months. The findings were evaluated after one year for hematological and molecular response achieved. Results: Fifteen (93.75{\%}) patients achieved complete hematological response within three months of therapy. Six (37.5{\%}) patients achieved complete molecular response(CMR) within six months of therapy as measured by real time RT Q-PCR. None of the patients who did not achieve CMR within first six months of therapy achieved it after one year of therapy. No patient lost the initial response. The median BCR - ABL/ABL value at the end of the six months was 11{\%} and at the end of the one year was 3.38{\%}. Conclusion: Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be used as a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.",
author = "A. Gupta and K. Prasad",
year = "2007",
month = "2",
day = "1",
language = "English",
volume = "55",
pages = "109--113",
journal = "The Journal of the Association of Physicians of India",
issn = "0004-5772",
publisher = "Journal of Association of Physicians of India",
number = "FEB.",

}

Hematological and molecular response evaluation of CML patients on imatinib. / Gupta, A.; Prasad, K.

In: Journal of Association of Physicians of India, Vol. 55, No. FEB., 01.02.2007, p. 109-113.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hematological and molecular response evaluation of CML patients on imatinib

AU - Gupta, A.

AU - Prasad, K.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background : The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. Aims : To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. Methods and Materials : Sixteen patients were diagnosed as having chronic phase CML at Kasturba Medical College Hospital, Attavar, Mangalore during the period of two years from January 2004 to January 2006 and were given Imatinib at 400 mg/day orally. They were followed closely over a period of 1 year using the following parameters: (1) monthly clinical examination, (2) monthly peripheral blood smear examination, (3) real time reverse transcriptase quantitative polymerase chain reaction (RT Q-PCR) for BCR-ABL at the end of every 6 months. The findings were evaluated after one year for hematological and molecular response achieved. Results: Fifteen (93.75%) patients achieved complete hematological response within three months of therapy. Six (37.5%) patients achieved complete molecular response(CMR) within six months of therapy as measured by real time RT Q-PCR. None of the patients who did not achieve CMR within first six months of therapy achieved it after one year of therapy. No patient lost the initial response. The median BCR - ABL/ABL value at the end of the six months was 11% and at the end of the one year was 3.38%. Conclusion: Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be used as a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.

AB - Background : The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. Aims : To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. Methods and Materials : Sixteen patients were diagnosed as having chronic phase CML at Kasturba Medical College Hospital, Attavar, Mangalore during the period of two years from January 2004 to January 2006 and were given Imatinib at 400 mg/day orally. They were followed closely over a period of 1 year using the following parameters: (1) monthly clinical examination, (2) monthly peripheral blood smear examination, (3) real time reverse transcriptase quantitative polymerase chain reaction (RT Q-PCR) for BCR-ABL at the end of every 6 months. The findings were evaluated after one year for hematological and molecular response achieved. Results: Fifteen (93.75%) patients achieved complete hematological response within three months of therapy. Six (37.5%) patients achieved complete molecular response(CMR) within six months of therapy as measured by real time RT Q-PCR. None of the patients who did not achieve CMR within first six months of therapy achieved it after one year of therapy. No patient lost the initial response. The median BCR - ABL/ABL value at the end of the six months was 11% and at the end of the one year was 3.38%. Conclusion: Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be used as a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.

UR - http://www.scopus.com/inward/record.url?scp=34247538990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247538990&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 109

EP - 113

JO - The Journal of the Association of Physicians of India

JF - The Journal of the Association of Physicians of India

SN - 0004-5772

IS - FEB.

ER -